Our study also revealed that GLP-1 RA use was associated with a significantly lower risk of cardiovascular diseases and cardiovascular mortality than GLP-1 RA no-use in patients with T2D and without viral hepatitis. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.